Which long‑acting injectable (depot) antipsychotics are weight‑neutral or have minimal impact on weight for an adult patient?

Weight-Neutral Long-Acting Injectable Antipsychotics

Aripiprazole LAI is the only depot antipsychotic with demonstrated weight-neutral or minimal weight-gain properties, making it the preferred long-acting injectable option when metabolic concerns are paramount. 1, 2

Available Depot Formulations and Weight Impact

First-Generation LAIs

• First-generation depot antipsychotics (haloperidol decanoate, fluphenazine decanoate) are generally weight-neutral but carry high risk of extrapyramidal symptoms, limiting their utility despite favorable metabolic profiles. 3

Second-Generation LAIs: Weight Profiles

Most weight-neutral option:

• Aripiprazole LAI demonstrates minimal weight gain (0 to 4.4 kg range in clinical trials), significantly less than other atypical antipsychotics. 2
• Recent 24-month data confirm aripiprazole LAI produces substantially less weight gain (3.7 kg or 0.8 BMI increase) compared to oral aripiprazole (11.0 kg or 3.5 BMI increase) in early psychosis patients. 4

Moderate weight-gain risk:

• Risperidone LAI (Risperdal Consta) causes moderate weight gain (1.9 to 7.2 kg range), placing it in the intermediate category. 2, 5
• Paliperidone LAI (Xeplion) has similar weight-gain profile to risperidone, as it is the active metabolite. 3

High weight-gain risk:

• Olanzapine pamoate depot causes substantial weight gain (3.8 to 16.2 kg range), comparable to oral olanzapine, and should be avoided when weight is a concern. 2, 5

Clinical Decision Algorithm

When selecting a depot antipsychotic with weight considerations:

1. First choice: Aripiprazole LAI for patients requiring metabolic neutrality 1, 2, 4

2. Second choice: Risperidone or paliperidone LAI if aripiprazole is contraindicated or ineffective, with metabolic monitoring 5, 3

3. Avoid: Olanzapine pamoate in patients with obesity, diabetes risk, or metabolic syndrome 1, 2

Important Caveats

• No depot formulations of ziprasidone or lurasidone (the most weight-neutral oral antipsychotics) are currently available, limiting options for patients requiring both depot administration and complete weight neutrality. 1, 2

• The LAI formulation of aripiprazole appears superior to oral aripiprazole for weight management, suggesting formulation-specific metabolic advantages beyond the active compound itself. 4

• All patients on depot antipsychotics require baseline and ongoing metabolic monitoring including weight, BMI, waist circumference, fasting glucose, HbA1c, and lipid panels regardless of agent selected. 6

• Weight gain with depot antipsychotics is mediated primarily through histamine H1-receptor antagonism in the hypothalamus, explaining why aripiprazole (with minimal H1 affinity) demonstrates the most favorable profile. 1, 6